AIM: Aptamers are oligonucleic acid or peptide molecules that bind to a specific target molecule in cells, thus may act as effective vehicles for drug or siRNA delivery. In this study we investigated the DNA aptamers that target human glioblastoma multiforme (GBM) cells overexpressing epidermal growth factor receptor variant III (EGFRvIII), which was linked to radiation and chemotherapeutic resistance of this most aggressive brain tumor. METHODS: A 73-mer ssDNA library containing molecules with 30 nt of random sequence flanked by two primer hybridization sites was chosen as the initial library. Cell systematic evolution of ligands by exponential enrichment (Cell-SELEX) method was used to select the DNA aptamers that target EGFRvIII. The binding affinity of the aptamers was measured using a cell-based biotin-avidin ELISA. RESULTS: After 14 rounds of selection, four DNA aptamers (32, 41, 43, and 47) that specifically bound to the EGFRvIII-overexpressing human glioma U87Δ cells with Kd values of less than 100 nmol/L were discovered. These aptamers were able to distinguish the U87Δ cells from the negative control human glioma U87MG cells and HEK293 cells. Aptamer 32 specifically bound to the EGFRvIII protein with an affinity similar to the EGFR antibody (Kd values of aptamer 32 and the EGFR antibody were 0.62±0.04 and 0.32±0.01 nmol/L, respectively), and this aptamer was localized in the cell nucleus. CONCLUSION: The DNA aptamers are promising molecular probes for the diagnosis and treatment of GBM.
AIM: Aptamers are oligonucleic acid or peptide molecules that bind to a specific target molecule in cells, thus may act as effective vehicles for drug or siRNA delivery. In this study we investigated the DNA aptamers that target humanglioblastoma multiforme (GBM) cells overexpressing epidermal growth factor receptor variant III (EGFRvIII), which was linked to radiation and chemotherapeutic resistance of this most aggressive brain tumor. METHODS: A 73-mer ssDNA library containing molecules with 30 nt of random sequence flanked by two primer hybridization sites was chosen as the initial library. Cell systematic evolution of ligands by exponential enrichment (Cell-SELEX) method was used to select the DNA aptamers that target EGFRvIII. The binding affinity of the aptamers was measured using a cell-based biotin-avidin ELISA. RESULTS: After 14 rounds of selection, four DNA aptamers (32, 41, 43, and 47) that specifically bound to the EGFRvIII-overexpressing humanglioma U87Δ cells with Kd values of less than 100 nmol/L were discovered. These aptamers were able to distinguish the U87Δ cells from the negative control humanglioma U87MG cells and HEK293 cells. Aptamer 32 specifically bound to the EGFRvIII protein with an affinity similar to the EGFR antibody (Kd values of aptamer 32 and the EGFR antibody were 0.62±0.04 and 0.32±0.01 nmol/L, respectively), and this aptamer was localized in the cell nucleus. CONCLUSION: The DNA aptamers are promising molecular probes for the diagnosis and treatment of GBM.
Authors: Irene P M Lau; Erika K S Ngan; Jacky F C Loo; Y K Suen; H P Ho; S K Kong Journal: Biochem Biophys Res Commun Date: 2010-04-14 Impact factor: 3.575
Authors: James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande Journal: Nat Biotechnol Date: 2006-06-25 Impact factor: 54.908
Authors: Isamu Okamoto; Lawrence C Kenyon; David R Emlet; Takeshi Mori; Ji-ichiro Sasaki; Susumu Hirosako; Yasuko Ichikawa; Hiroto Kishi; Andrew K Godwin; Masakazu Yoshioka; Moritaka Suga; Mitsuhiro Matsumoto; Albert J Wong Journal: Cancer Sci Date: 2003-01 Impact factor: 6.716
Authors: Frank B Furnari; Tim Fenton; Robert M Bachoo; Akitake Mukasa; Jayne M Stommel; Alexander Stegh; William C Hahn; Keith L Ligon; David N Louis; Cameron Brennan; Lynda Chin; Ronald A DePinho; Webster K Cavenee Journal: Genes Dev Date: 2007-11-01 Impact factor: 11.361
Authors: Christopher E Pelloski; Karla V Ballman; Alfred F Furth; Li Zhang; E Lin; Erik P Sulman; Krishna Bhat; J Matthew McDonald; W K Alfred Yung; Howard Colman; Shiao Y Woo; Amy B Heimberger; Dima Suki; Michael D Prados; Susan M Chang; Fred G Barker; Jan C Buckner; C David James; Kenneth Aldape Journal: J Clin Oncol Date: 2007-06-01 Impact factor: 44.544
Authors: Koji Yoshimoto; Julie Dang; Shaojun Zhu; David Nathanson; Tiffany Huang; Rebecca Dumont; David B Seligson; William H Yong; Zhenggang Xiong; Nagesh Rao; Henrik Winther; Arnab Chakravarti; Darell D Bigner; Ingo K Mellinghoff; Steve Horvath; Webster K Cavenee; Timothy F Cloughesy; Paul S Mischel Journal: Clin Cancer Res Date: 2008-01-15 Impact factor: 12.531
Authors: Khaled S Allemailem; Ahmad Almatroudi; Mohammed A Alsahli; Ghaiyda Talal Basfar; Faris Alrumaihi; Arshad Husain Rahmani; Amjad Ali Khan Journal: 3 Biotech Date: 2020-11-24 Impact factor: 2.406